Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Address:

477 Madison Avenue, New York, United States

SteveStachion Jan. 31 at 2:35 AM

$HYPD $HYPE.X $PURR 👇👇👇

0 · Reply

Jackie_Treehorn Jan. 31 at 1:08 AM

$PURR

0 · Reply

insanitywolftrading Jan. 30 at 9:02 PM

$PURR $HYPE.X

0 · Reply

insanitywolftrading Jan. 30 at 7:03 PM

$PURR $HYPE.X haha look at that

0 · Reply

insanitywolftrading Jan. 30 at 5:57 PM

$HYPE.X $PURR Phantom just sent a push notification to possibly everyone about HYPE, either very bullish or very bearish

0 · Reply

insanitywolftrading Jan. 30 at 2:45 PM

$HYPE.X $PURR Are you seeing what I'm seeing? The volume on trading RWAs is absolutely fucking insane. Something is happening.

0 · Reply

IslandBoyInvest Jan. 29 at 8:40 PM

$PURR why are you guys buying this instead of hyperliquid ? It’s not like it’s a 2X I don’t seethe benefit

0 · Reply

Kgrass Jan. 28 at 8:36 PM

$PURR Appears to be struggling to hold the bottom up. 🤔🤔🤔🤔🤔 Still not seeing the bullish behavior??

0 · Reply

ChazzyTrades Jan. 28 at 7:31 PM

$QQQ $SPY this week was horrible. $BATL absolutely killed me then i bought it a couple days later and it killed me again. Then i had bought $PURR and sold at the bottom and it has risen ever since. Someone please take my money

1 · Reply

JoseBadass Jan. 28 at 5:21 PM

$PURR We bounce

0 · Reply

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 2 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 2 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 2 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 3 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 4 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 6 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 6 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 11:30 AM EDT - 7 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 6:00 AM EDT - 7 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 9 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 10 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 10 months ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 10 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 11 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 11 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 11 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 6, 2024, 7:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

SteveStachion Jan. 31 at 2:35 AM

$HYPD $HYPE.X $PURR 👇👇👇

0 · Reply

Jackie_Treehorn Jan. 31 at 1:08 AM

$PURR

0 · Reply

insanitywolftrading Jan. 30 at 9:02 PM

$PURR $HYPE.X

0 · Reply

insanitywolftrading Jan. 30 at 7:03 PM

$PURR $HYPE.X haha look at that

0 · Reply

insanitywolftrading Jan. 30 at 5:57 PM

$HYPE.X $PURR Phantom just sent a push notification to possibly everyone about HYPE, either very bullish or very bearish

0 · Reply

insanitywolftrading Jan. 30 at 2:45 PM

$HYPE.X $PURR Are you seeing what I'm seeing? The volume on trading RWAs is absolutely fucking insane. Something is happening.

0 · Reply

IslandBoyInvest Jan. 29 at 8:40 PM

$PURR why are you guys buying this instead of hyperliquid ? It’s not like it’s a 2X I don’t seethe benefit

0 · Reply

Kgrass Jan. 28 at 8:36 PM

$PURR Appears to be struggling to hold the bottom up. 🤔🤔🤔🤔🤔 Still not seeing the bullish behavior??

0 · Reply

ChazzyTrades Jan. 28 at 7:31 PM

1 · Reply

JoseBadass Jan. 28 at 5:21 PM

$PURR We bounce

0 · Reply

LORAXX Jan. 28 at 5:09 PM

$PURR Back up we go!

0 · Reply

Kgrass Jan. 28 at 4:50 PM

$PURR If $4.35 does not hold, then we are back to yesterday’s open at 4.05. Then possibly a gap fill. For an extremely Bullish stock, it’s looking quite Bearish.🤔🤔🤔🤔🤔

0 · Reply

ChazzyTrades Jan. 28 at 4:11 PM

$PURR lool they are fricken begging me to sell. Crazy

0 · Reply

insanitywolftrading Jan. 28 at 3:02 PM

$PURR hell yeah we’re pissing all over $MSTR

0 · Reply

insanitywolftrading Jan. 28 at 2:56 PM

$PURR lol who sold

0 · Reply

ChazzyTrades Jan. 28 at 2:46 PM

$PURR just hold

0 · Reply

jacda1337 Jan. 28 at 2:46 PM

$PURR BRUHHHH ANYTIME NAO

0 · Reply

jacda1337 Jan. 28 at 2:38 PM

$PURR here comes the boom

0 · Reply

jacda1337 Jan. 28 at 2:35 PM

$PURR volume def pouring in

0 · Reply

jacda1337 Jan. 28 at 2:32 PM

$PURR she wants to run today

0 · Reply

jacda1337 Jan. 28 at 2:26 PM

$PURR might pull a xtkg related to crypto

0 · Reply

jacda1337 Jan. 28 at 2:25 PM

$PURR this will explosion anytime soon

0 · Reply

Market Cap	555.10M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	11.62
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	4,618,900
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	127.03M
Stochastic %K	69%
Beta	1.51
Analysts	Strong Sell
Price Target	$6.58